AstraZeneca Archives

La Alianza MSD-AstraZeneca remarcan la importancia de la atención integral en pacientes con cáncer de ovario

Se considera que abordar la enfermedad de una manera multidisciplinar es esencial para que las pacientes con cáncer de ovario

MSD y AstraZeneca han presentado los resultados finales del criterio de valoración secundario clave de supervivencia global del ensayo fase

Olaparib en combinación con abiraterona aprobado en la UE como tratamiento para pacientes con cáncer de próstata metastásico resistente a

Cookie	Duración	Descripción
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.